Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome

The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes

(2018) Grace McMacken et al.   HUMAN MOLECULAR GENETICS

Postnatal Development and Distribution of Sympathetic Innervation in Mouse Skeletal Muscle

(2018) Tatjana Straka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Trans-synaptic homeostasis at the myasthenic neuromuscular junction

(2017) Jaap J Plomp   Frontiers in Bioscience-Landmark

The Structure of Human Neuromuscular Junctions: Some Unanswered Molecular Questions

(2017) Clarke Slater   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Increasing Genetic and Phenotypical Diversity of Congenital Myasthenic Syndromes

(2017) Angela Abicht et al.   NEUROPEDIATRICS

NMJ-morph reveals principal components of synaptic morphology influencing structure–function relationships at the neuromuscular junction

(2016) Ross A. Jones et al.   Open Biology

Salbutamol benefits children with congenital myasthenic syndrome due to ALG2 mutation

(2015) M. Salih et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment

(2015) Andrew G Engel et al.   LANCET NEUROLOGY

Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes

(2015) Pedro M. Rodríguez Cruz et al.   NEUROLOGY

Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy

(2014) Sophie Nicole et al.   BRAIN

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

(2014) Nigel Tse et al.   Jove-Journal of Visualized Experiments

β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders

(2013) Olivier R. Joassard et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation

(2013) Paulo J. Lorenzoni et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK

(2013) Constanze Gallenmüller et al.   NEUROMUSCULAR DISORDERS

Effects ofin vivoinjury on the neuromuscular junction in healthy and dystrophic muscles

(2012) Stephen J.P. Pratt et al.   JOURNAL OF PHYSIOLOGY-LONDON

Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations

(2012) Georgina Burke et al.   NEUROMUSCULAR DISORDERS

Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia

(2011) Teerin Liewluck et al.   MUSCLE & NERVE

Muscle Specific Kinase: Organiser of synaptic membrane domains

(2010) Nazanin Ghazanfari et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

ColQ Controls Postsynaptic Differentiation at the Neuromuscular Junction

(2010) S. M. Sigoillot et al.   JOURNAL OF NEUROSCIENCE

Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7

(2010) D. Lashley et al.   NEUROLOGY

Structural Factors Influencing the Efficacy of Neuromuscular Transmission

(2008) Clarke R. Slater   Annals of the New York Academy of Sciences

Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes

(2008) Violeta Mihaylova et al.   BRAIN

Daily salbutamol in young patients with SMA type II

(2008) Marika Pane et al.   NEUROMUSCULAR DISORDERS

Therapeutic strategies in congenital myasthenic syndromes

(2008) Ulrike Schara et al.   Neurotherapeutics

Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study

(2008) Silvia Mandillo et al.   PHYSIOLOGICAL GENOMICS

Role of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease

(2008) Gordon S. Lynch et al.   PHYSIOLOGICAL REVIEWS